Arlington Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Arlington Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Hold	500	–	–	0.03%	95
2026 Q1	$223K	Hold	500	–	–	0.03%	91
2025 Q4	$227K	Buy	+500	New	+$216K	0.03%	97
2025 Q3	–	Sell	-500	Closed	-$223K	–	113
2025 Q2	$223K	Sell	500 -40	-7%	-$18.4K	0.04%	80
2025 Q1	$262K	Buy	540 +5	+0.9%	+$2.33K	0.05%	97
2024 Q4	$215K	Buy	535 +35	+7%	+$16.2K	0.04%	90
2024 Q3	$233K	Sell	500 -35	-7%	-$16.8K	0.05%	69
2024 Q2	$251K	Buy	535 +35	+7%	+$15.2K	0.06%	63
2024 Q1	$209K	Hold	500	–	–	0.05%	70
2023 Q4	$203K	Buy	+500	New	+$185K	0.06%	77
2020 Q4	–	Sell	-900	Closed	-$245K	–	62
2020 Q3	$245K	Hold	900	–	–	0.13%	50
2020 Q2	$261K	Hold	900	–	–	0.15%	53
2020 Q1	$214K	Buy	+900	New	+$206K	0.15%	48

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Arlington Financial Advisors's VRTX Position: Q2 2026 in Review

Arlington Financial Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 500 shares worth $248K. The position accounts for 0.03% of the portfolio, ranked #95.

Arlington Financial Advisors first reported a position in VRTX in Q1 2020 and has held it in 13 quarters since. The position peaked at $262K in Q1 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Arlington Financial Advisors held 500 shares of Vertex Pharmaceuticals worth $248K as of Q2 2026.
Arlington Financial Advisors left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.03% of Arlington Financial Advisors's portfolio in Q2 2026, its #95 holding.
Arlington Financial Advisors first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 13 quarters since.
Arlington Financial Advisors's Vertex Pharmaceuticals position peaked at $262K in Q1 2025.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Arlington Financial Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.